Nightstar Therapeutics PLC (NITE):製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Nightstar Therapeutics PLC (NITE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C9415)・商品コード:DATA904C9415
・発行会社(調査会社):GlobalData
・発行日:2018年11月
・ページ数:35
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Nightstar Therapeutics PLC (Nightstar Therapeutics), formerly Nightstar Therapeutics Ltd, is a clinical-stage gene therapy company. The company focus on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases. Its lead product candidate is NSR-REP1, a candidate that is in phase 3 clinical development for the treatment of patients with choroideremia; and NSR-RPGR, a candidate that is in Phase 1/2 clinical trials for the treatment of patients with X-linked retinitis pigmentosa, an inherited X-linked recessive retinal disease. The company also develops NSR-BEST1, a candidate that is in preclinical development stage for the treatment of best vitelliform macular dystrophy; and NSR-ABCA4, a candidate that is in preclinical development stage for the treatment of Stargardt disease. It develops retinal gene therapies for patients suffering from rare inherited retinal disease. Nightstar Therapeutics is headquartered in London, the UK.

Nightstar Therapeutics PLC (NITE) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Nightstar Therapeutics PLC, Medical Devices Deals, 2012 to YTD 2018 9
Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
NightstaRx Raises USD45 Million in Series C Financing 11
NightstaRx Raises USD35 Million in Series B Financing Round 12
Nightstar Raises Additional USD8.2 Million in Venture Financing Round 13
NightstaRx Raises US$19.8 Million In Venture Financing 14
Licensing Agreements 15
Nightstar Therapeutics Enters into Licensing Agreement with Oxford University Innovation 15
NightstaRx Enters into Licensing Agreement with Oxford University 16
NightstaRx Expands Licensing Agreement with Isis Innovation 17
NightstaRx Enters into Licensing Agreement with Oxford University Innovation 18
Equity Offering 19
Nightstar Therapeutics Raises USD86.3 Million in Public Offering of American Depository Shares 19
Nightstar Therapeutics Raises USD86.3 Million in IPO 21
Nightstar Therapeutics PLC – Key Competitors 23
Nightstar Therapeutics PLC – Key Employees 24
Nightstar Therapeutics PLC – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 26
Financial Announcements 26
Aug 13, 2018: Nightstar Therapeutics reports second quarter 2018 financial results and business highlights 26
Jun 06, 2018: Nightstar Therapeutics Reports First Quarter 2018 Financial Results 28
Apr 03, 2018: Nightstar Therapeutics Reports 2017 Financial Results and Business Highlights 29
Corporate Communications 31
Sep 13, 2018: Nightstar Therapeutics names Paula Cobb as Board Director 31
Product News 32
03/19/2017: NightstaRx Commences first Phase I/II Gene Therapy Clinical Trial for Patients with X-Linked Retinitis Pigmentosa 32
Clinical Trials 33
Mar 05, 2018: Nightstar Therapeutics Announces Initiation of STAR Phase 3 Registrational Trial for NSR-REP1 in Choroideremia 33
Other Significant Developments 34
Oct 09, 2018: Gene therapy breakthrough in treating a rare form of blindness 34
Appendix 35
Methodology 35
About GlobalData 35
Contact Us 35
Disclaimer 35

List of Tables
Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Nightstar Therapeutics PLC, Deals By Therapy Area, 2012 to YTD 2018 8
Nightstar Therapeutics PLC, Medical Devices Deals, 2012 to YTD 2018 9
Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
NightstaRx Raises USD45 Million in Series C Financing 11
NightstaRx Raises USD35 Million in Series B Financing Round 12
Nightstar Raises Additional USD8.2 Million in Venture Financing Round 13
NightstaRx Raises US$19.8 Million In Venture Financing 14
Nightstar Therapeutics Enters into Licensing Agreement with Oxford University Innovation 15
NightstaRx Enters into Licensing Agreement with Oxford University 16
NightstaRx Expands Licensing Agreement with Isis Innovation 17
NightstaRx Enters into Licensing Agreement with Oxford University Innovation 18
Nightstar Therapeutics Raises USD86.3 Million in Public Offering of American Depository Shares 19
Nightstar Therapeutics Raises USD86.3 Million in IPO 21
Nightstar Therapeutics PLC, Key Competitors 23
Nightstar Therapeutics PLC, Key Employees 24
Nightstar Therapeutics PLC, Subsidiaries 25

List of Figures
Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Nightstar Therapeutics PLC, Medical Devices Deals, 2012 to YTD 2018 9

★調査レポート[Nightstar Therapeutics PLC (NITE):製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C9415)販売に関する免責事項を必ずご確認ください。
★調査レポート[Nightstar Therapeutics PLC (NITE):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆